Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryDespite ongoing efforts to revive Elevidys, Sarepta Therapeutics conveys a realistic and measured approach to its growth prospects, emphasizing the complexity and time required for sustained recovery in the gene therapy field.
Dr. Priya NandakumarMay 7, 2026
Regulatory & PolicyLeadership stability is crucial to effective public health policy and regulatory oversight. However, recent turnover rates at the U.S. Department of Health and Human Services' major public health agencies signal ongoing challenges in maintaining consistent governance and oversight at the FDA and CDC.
Dr. Priya NandakumarMay 7, 2026
Biopharmaceutical IndustryIn response to supply chain challenges and rising demand in outsourced fill/finish services, PCI is more than doubling its capacity to fill prefilled syringes and cartridges for pharmaceuticals. This strategic expansion underscores the growing importance of sterile drug delivery technologies in the biopharma sector.
Dr. Priya NandakumarMay 4, 2026
Healthcare InvestmentIn April 2026, the biotechnology sector experienced a major capital boost as four biotech companies joined public markets through upsized IPOs, raising a record $1.5 billion. Companies such as Hemab Therapeutics and Seaport Therapeutics led this wave, signaling renewed optimism in biotech innovation and investment.
Dr. Priya NandakumarMay 3, 2026
Regulatory & PolicyStudies and FDA reports indicate the presence of 'forever chemicals' in infant nutrition products, prompting scientific scrutiny and discussions about regulatory thresholds and consumer safety in 2026.
Dr. Priya NandakumarMay 1, 2026
Biopharmaceutical IndustryAmgen's investigational drug MariTide represents a significant innovation in managing obesity by potentially enabling monthly or less frequent dosing schedules, promising enhanced patient adherence and convenience. This approach could position MariTide as a competitive solution in the obesity drug market, addressing treatment adherence challenges and meeting a substantial unmet medical need.
Dr. Priya NandakumarMay 1, 2026
Regulatory & PolicyFacing rigorous FDA scrutiny, AstraZeneca must address critical concerns regarding data integrity and clinical efficacy as part of its ongoing regulatory review. This post examines the key challenges at play, potential impact on market access, and the wider implications for regulatory pathways in the biopharma industry.
Dr. Priya NandakumarApr 29, 2026
Biotech InnovationAt the 2026 annual meeting of the American Association for Cancer Research (AACR), key topics included the increasing prominence of Chinese biotech companies in the arena of cancer research alongside an examination of ongoing communication issues in oncology. These discussions reflect broader trends in global biotech innovation and highlight critical barriers that impact how oncology research and treatments are conveyed among stakeholders.
Dr. Priya NandakumarApr 22, 2026
Regulatory & PolicyThe regulatory landscape for pharmaceutical manufacturing is continually evolving, with the FDA maintaining rigorous standards to ensure drug safety and efficacy. Recent events involving a GLP-1 receptor agonist manufacturer refusing FDA inspection access have cast light on the complexities and challenges regulators face in enforcing compliance. This article explores the implications of such regulatory confrontations, the manufacturer’s stance, and the broader context of FDA oversight.
Dr. Priya NandakumarApr 22, 2026
Healthcare InvestmentIn the first quarter of 2026, UnitedHealth exceeded analyst forecasts in both its Optum and UnitedHealthcare businesses. However, the company continues to face ongoing hurdles in the evolving healthcare landscape, reflecting complex market dynamics.
Dr. Priya NandakumarApr 21, 2026
Regulatory & PolicyErica Schwartz, former deputy surgeon general and military physician, is positioned to inherit leadership of the CDC. The nomination has sparked a complex response within the agency characterized by cautious hopefulness, tempered by the political influence of Health Secretary RFK Jr. This development marks a critical juncture for an agency wrestling with internal and external challenges.
Dr. Priya NandakumarApr 18, 2026
Regulatory & PolicyRecent feedback from biopharma industry leaders indicates that the FDA is exhibiting varying degrees of flexibility. While some executives commend the agency’s collaborative stance, others point to inconsistencies that highlight the growing pains in adapting regulations to foster innovation in rare disease treatments.
Dr. Priya NandakumarApr 13, 2026